If within the studies it shows a reduction/slowing of brain mass reduction, it would be a massive benefit to the study, and proven need for the drug, something the FDA could not refuse.
And by doing/possibly adding this, I believe they are most likely seeing this within the studies.
I didnt take any negative feedback from this preso.
If anything the SP may drop due to having to wait alittle longer, or SH were probably wanting more insight into study results, but they both seem keen to release the report in July.
ATH Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)